BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 6886282)

  • 41. Bioavailability of ergoloid mesylates liquid capsule.
    Schran HF
    Clin Ther; 1985; 8(1):71-5. PubMed ID: 3833371
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The hydergine test in postoperative urological patients over 70 years of age].
    FRATELLO U; FIORE A; CIOFFI L
    Minerva Urol; 1962; 14():159-63. PubMed ID: 13959354
    [No Abstract]   [Full Text] [Related]  

  • 43. Relieving select symptoms of the elderly.
    Nelson JJ
    Geriatrics; 1975 Mar; 30(3):133-9, 142. PubMed ID: 803912
    [No Abstract]   [Full Text] [Related]  

  • 44. [19 CASES OF SUDEK-KIENBOECK ACUTE ATROPHY TREATED WITH HYDERGINE].
    RONCALLI-BENEDETTI L; SOAVE G
    Minerva Chir; 1964 May; 19():363-6. PubMed ID: 14158733
    [No Abstract]   [Full Text] [Related]  

  • 45. [VALUE OF CUPULOMETRY IN THE CONTROL AND TREATMENT OF VERTIGO. APROPOS OF THE ACTION OF HYDERGINE].
    DECROIX G; NICOLAS G; MASSOL P; TREFFEL M
    Ann Otolaryngol Chir Cervicofac; 1963 Dec; 80():947-57. PubMed ID: 14100718
    [No Abstract]   [Full Text] [Related]  

  • 46. Electroencephalogram and ergot alkaloids.
    Venn RD
    Postgrad Med J; 1976; 52suppl 1():55-6. PubMed ID: 822408
    [No Abstract]   [Full Text] [Related]  

  • 47. Hydergine: interaction with the neurotransmitter systems in the central nervous system.
    Markstein R
    J Pharmacol; 1985; 16 Suppl 3():1-17. PubMed ID: 2869188
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical evaluation of combined hydrogenated ergot alkaloids (hydergine) in arterial hypertension with special reference to their action in central manifestations.
    TANDOWSKY RM
    Circulation; 1954 Jan; 9(1):48-56. PubMed ID: 13116375
    [No Abstract]   [Full Text] [Related]  

  • 49. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
    Kisicki JC; Fiske K; Lyne A
    Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The hydrogenated ergot alkaloids (hydergine); a hypotensive agent.
    SCHULTZ FB
    Am Pract Dig Treat; 1953 May; 4(5):330-6. PubMed ID: 13050917
    [No Abstract]   [Full Text] [Related]  

  • 51. THE EFFECT OF TOPICALLY USED HYDERGINE ON OCULAR TENSION.
    DIOTALLEVI M; AURICCHIO G
    Ophthalmologica; 1964; 147():448-54. PubMed ID: 14167874
    [No Abstract]   [Full Text] [Related]  

  • 52. [Prevention of drepanocytic painful crises with hydergine].
    Cuisinier JC; Ducloux M; Lagarde B; Barbotin M; Darracq R
    Bull Soc Med Afr Noire Lang Fr; 1974; 19(2):168-72. PubMed ID: 4219596
    [No Abstract]   [Full Text] [Related]  

  • 53. Dihydroergotoxine(Hydergine) and ethanol-induced aging of C57BL/6J male mice.
    Samorajski T; Rolsten C; Pratte KA
    Pharmacology; 1978; 16 Suppl 1():36-44. PubMed ID: 643904
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sinus bradycardia following treatment with hydergine for cerebrovascular insufficiency.
    Dcayley AC; Macpherson A; Wedgwood J
    Br Med J; 1975 Nov; 4(5993):384-5. PubMed ID: 811310
    [No Abstract]   [Full Text] [Related]  

  • 55. [Treatment of thrombophlebitis of the lower extremity with panthesin and hydergine (PH-203)].
    CISEK T; ARONSKI A; MASLANKA P
    Pol Tyg Lek; 1962 Apr; 17():710-3. PubMed ID: 13879603
    [No Abstract]   [Full Text] [Related]  

  • 56. [ACTION OF HYDERGINE ON HUMAN EYES AFFECTED BY VARIOUS FORMS OF HYPERTENSION].
    DIOTALLEVI M; AURICCHIO G
    Ann Ottalmol Clin Ocul; 1964 Jun; 90():322-4. PubMed ID: 14210355
    [No Abstract]   [Full Text] [Related]  

  • 57. [FOLLOW-UP TREATMENT OF CEREBROCRANIAL INJURIES WITH HYDERGINE].
    AMANN E; GERSTENBRAND F
    Acta Neurochir (Wien); 1964; 11():751. PubMed ID: 14213902
    [No Abstract]   [Full Text] [Related]  

  • 58. [On the prophylaxis and therapy of thromboembolism. Experiences with PH 203 (panthesin plus hydergine)].
    RUBELI HH; KRULL J
    Schweiz Med Wochenschr; 1959 Oct; 89():1153-8. PubMed ID: 14439834
    [No Abstract]   [Full Text] [Related]  

  • 59. Observations on the use of PH 203 and hydergine in some circulatory disturbances of the fundus and vascular retinopathy.
    ORMA H; VANNAS S
    Acta Ophthalmol (Copenh); 1958; 36(4):734-49. PubMed ID: 13594388
    [No Abstract]   [Full Text] [Related]  

  • 60. The effect of hydergine on the cardiovascular system of elderly people: electrocardiographic and ballistocardiographic studies.
    ARAVANIS C; HARRIS R
    J Am Geriatr Soc; 1959 Dec; 7():920-7. PubMed ID: 13794030
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.